Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients

New labeling approval for Abbott's XIENCE™ stent builds on a legacy of safety and allows for one-month (as short as 28 days) dual anti-platelet therapy (DAPT) for patients at high bleeding risk (HBR) The new XIENCE Skypoint™ stent received FDA approval ... Devices, Interventional, Cardiology, FDA Abbott, XIENCE, stent, dual anti-platelet therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news